Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

GSK5460025

PreclinicalSmall molecule

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Neoplasms,colorectalRecruiting

Neoplasms,colorectalPreclinical

Recruiting

Timeline

Expected Milestones

Q4 2028

PreclinicalRecruiting

Neoplasms,colorectal

NCT07213609

Clinical

Trials by Indication[1]

Neoplasms,Colorectal1 trial

A Phase 1/2 Open-label, Multicenter Study of Oral GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Adult Participants With Mismatch Repair-deficient (dMMR) or Microsatellite Instability-High (MSI-H) Solid Tumors

Recruiting· GSK logo

GSK·Preclinical·NCT07213609·47 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for GSK5460025. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GSK5460025 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GSK5460025. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: GSK

Related News